<DOC>
	<DOCNO>NCT00246649</DOCNO>
	<brief_summary>An autologous peripheral stem cell bone marrow transplant may able replace blood-forming cell destroy chemotherapy . Using stem cell bone marrow cell treat laboratory may effective treatment acute leukemia . This clinical trial study well autologous stem cell transplant use specially treat cell work treat patient acute leukemia .</brief_summary>
	<brief_title>Stem Cell Transplant With Specially Treated Cells Treating Patients With Acute Leukemia</brief_title>
	<detailed_description>Patients receive infusion cyclophosphamide infusion injection G-CSF day 7-14 day follow collection peripheral stem cell . Some patient may also undergo bone marrow collection . Patients ' stem cell and/or bone marrow treat laboratory . Patients receive busulfan 4 day follow cyclophosphamide 4 day . Two day later , patient undergo autologous peripheral stem cell bone marrow transplant receive infusion injection G-CSF day blood count return normal . The goal pilot clinical study shorten duration aplasia associate mafosfamide purge autologous transplant acute leukemia use cytokine cocktail recombinant human stem cell factor ( rhSCF ) , recombinant human granulocyte colony stimulate factor ( rhG-CSF ) recombinant human thrombopoeitin ( rhTPO ) ex vivo expansion . After finish treatment , patient evaluate periodically least 5 year .</detailed_description>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Mafosfamide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>AML high risk CR1 without match family donor AML CR2 without HLAidentical sibling donor High Risk ALL HLAidentical sibling donor Available suitable match HLAidentical sibling donor Intermediate goodrisk leukemia</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Mafosfamide</keyword>
	<keyword>Growth Factor</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Bone Marrow</keyword>
</DOC>